Literature DB >> 7499257

Effects of protein S and factor Xa on peptide bond cleavages during inactivation of factor Va and factor VaR506Q by activated protein C.

J Rosing1, L Hoekema, G A Nicolaes, M C Thomassen, H C Hemker, K Varadi, H P Schwarz, G Tans.   

Abstract

Inactivation of membrane-bound factor Va by activated protein C (APC) proceeds via a biphasic reaction that consists of a rapid and a slow phase, which are associated with cleavages at Arg506 and Arg306 of the heavy chain of factor Va, respectively. We have investigated the effects of protein S and factor Xa on APC-catalyzed factor Va inactivation. Protein S accelerates factor Va inactivation by selectively promoting the slow cleavage at Arg306 (20-fold). Factor Xa protects factor Va from inactivation by APC by selectively blocking cleavage at Arg506. Inactivation of factor VaR506Q, which was isolated from the plasma of a homozygous APC-resistant patient and which lacks the Arg506 cleavage site, was also stimulated by protein S but was not affected by factor Xa. This confirms that the target sites of protein S and factor Xa involve Arg306 and Arg506, respectively. Factor Xa completely blocked APC-catalyzed cleavage at Arg506 in normal factor Va (1 nM) with a half-maximal effect (K1/2Xa) at 1.9 nM factor Xa. Expression of cofactor activity of factor Va in prothrombin activation required much lower factor Xa concentrations (K1/2Xa = 0.08 nM). When the ability of factor Xa to protect factor Va from inactivation by APC was determined at low factor Va concentrations during prothrombin activation much lower amounts of factor Xa were required (K1/2Xa = 0.03 nM). This indicates 1) that factor Va is optimally protected from inactivation by APC by incorporation into the prothrombinase complex during ongoing prothrombin activation, and 2) that the formation of a catalytically active prothrombinase complex and protection of factor Va from inactivation by APC likely involves the same interaction of factor Xa with factor Va. In accordance with the proposed mechanisms of action of protein S and factor Xa, we observed that the large differences between the rates of APC-catalyzed inactivation of normal factor Va and factor VaR506Q were almost annihilated in the presence of factor Xa and protein S. This observation may explain why, in the absence of other risk factors, APC resistance only results in a weak prothrombotic condition.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7499257     DOI: 10.1074/jbc.270.46.27852

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

1.  Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va.

Authors:  Thomas J Cramer; John H Griffin; Andrew J Gale
Journal:  Pathophysiol Haemost Thromb       Date:  2010-05-22

2.  The functional significance of the autolysis loop in protein C and activated protein C.

Authors:  Likui Yang; Chandrashekhara Manithody; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2005-07       Impact factor: 5.249

3.  Gly74Ser mutation in protein C causes thrombosis due to a defect in protein S-dependent anticoagulant function.

Authors:  Changming Chen; Likui Yang; Bruno O Villoutreix; Xuefeng Wang; Qiulan Ding; Alireza R Rezaie
Journal:  Thromb Haemost       Date:  2017-04-13       Impact factor: 5.249

4.  Autolysis loop restricts the specificity of activated protein C: analysis by FRET and functional assays.

Authors:  Shabir H Qureshi; Chandrashekhara Manithody; Jong-Sup Bae; Likui Yang; Alireza R Rezaie
Journal:  Biophys Chem       Date:  2008-02-25       Impact factor: 2.352

5.  The Journey of Protein S from an Anticoagulant to a Signaling Molecule.

Authors:  V S Pilli; William Plautz; Rinku Majumder
Journal:  JSM Biochem Mol Biol       Date:  2016-08-08

6.  Generation and phenotypic analysis of protein S-deficient mice.

Authors:  François Saller; Anne C Brisset; Svetlana N Tchaikovski; Monica Azevedo; Roman Chrast; José A Fernández; Marc Schapira; Tilman M Hackeng; John H Griffin; Anne Angelillo-Scherrer
Journal:  Blood       Date:  2009-06-30       Impact factor: 22.113

7.  Characterization of mini-protein S, a recombinant variant of protein S that lacks the sex hormone binding globulin-like domain.

Authors:  M Van Wijnen; J G Stam; G T Chang; J C Meijers; P H Reitsma; R M Bertina; B N Bouma
Journal:  Biochem J       Date:  1998-02-15       Impact factor: 3.857

8.  Implication of protein S thrombin-sensitive region with membrane binding via conformational changes in the gamma-carboxyglutamic acid-rich domain.

Authors:  D Borgel; P Gaussem; C Garbay; C Bachelot-Loza; T Kaabache; W Q Liu; B Brohard-Bohn; B Le Bonniec; M Aiach; S Gandrille
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

9.  Inhibition of thrombin formation by active site mutated (S360A) activated protein C.

Authors:  Gerry A F Nicolaes; Paul E Bock; Kenneth Segers; Karin C A A Wildhagen; Björn Dahlbäck; Jan Rosing
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

10.  The effect of Arg306-->Ala and Arg506-->Gln substitutions in the inactivation of recombinant human factor Va by activated protein C and protein S.

Authors:  J O Egan; M Kalafatis; K G Mann
Journal:  Protein Sci       Date:  1997-09       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.